Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 18

Explainer

CJC-1295 / Ipamorelin and Sleep Disruption

A CJC-1295 and ipamorelin blend can deepen early sleep and then fragment the rest of the night. The pharmacology of GH pulse timing explains why.

22 Jul 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

HGH and tesamorelin: reason to combine?

Tesamorelin stimulates the pituitary to release endogenous GH. Exogenous HGH bypasses it entirely. No clinical trial has evaluated the combination.

22 Jul 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

SOUL trial: HbA1c predicts heart benefit

A July 2026 JCEM analysis of the SOUL trial found oral semaglutide's MACE benefit tracks glycaemic response more than body weight change.

22 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Respiratory safety of weight-loss drugs

A July 2026 ATS meta-analysis of 123 studies finds no added respiratory harm from four major weight-loss drugs, but flags a gap in asthma-specific evidence.

22 Jul 2026 · PeptideMethods Editorial Team · 3 min read
Explainer

Semaglutide in India: the paediatric gap

Indian generic semaglutide has adult non-inferiority data. A 2026 letter in Indian Pediatrics asks what expanded access means for adolescents.

21 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Compounders hold on in the GLP-1 market

A June 2026 Gallup survey found nearly 1 in 5 GLP-1 users still take compounded versions, despite FDA crackdowns and pharma lawsuits.

21 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

GLP-1 and opioid overdose risk in veterans

A 2026 VHA study linked semaglutide and tirzepatide to lower overdose rates than insulin and SGLT2 inhibitors in veterans with T2D and opioid use disorder.

21 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

NVAC charter, GLP-1 telehealth: July 2026

NVAC gets a new charter on 7 July 2026, LifeMD faces GLP-1 telehealth allegations, and Medicare proposes 19% more pay for tobacco counselling.

21 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

TTT1: triple therapy for type 1 diabetes

The TTT1 Phase 3 trial tests semaglutide and dapagliflozin added to insulin in overweight adults with type 1 diabetes and poor glycaemic control.

21 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Surgery vs semaglutide: Reddit concerns

NLP of 45,972 Reddit comments: surgery patients cite pain; semaglutide users cite GI and psychological effects. Pre-op anxiety runs 4x higher than post-op.

21 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semax and Selank: normal, N-Acetyl, Amidate

N-Acetyl and Amidate caps extend peptide half-life by blocking degradation, not by changing the receptor mechanism. Here is the biochemistry.

21 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

LifeMD GLP-1 safety claims and Iowa's PBM

Former LifeMD employees allege GLP-1 prescriptions were rushed. An Iowa audit found a PBM may have overcharged Medicaid by over $100 million.

21 Jul 2026 · PeptideMethods Editorial Team · 4 min read